Management and therapy for cardiomyopathy in Friedreich's ataxia

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 6, 2012, Pages 767-777

  Lynch, David R ^a   Regner, Sean R ^a   Schadt, Kimberly A ^a   Friedman, Lisa S ^a   Lin, Kimberly Y ^a   Sutton, Martin G St John ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

antioxidant; cardiomyopathy; clinical measure; dorsal root ganglion; epigenetic; hypertrophic; mitochondrion

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DEFERIPRONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; FERRITIN; FERROPORTIN; FRATAXIN; HISTONE DEACETYLASE INHIBITOR; IDEBENONE; IRON; LIPOFUSCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE; UBIQUINONE;

ALLELE; CARDIAC IMAGING; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CLINICAL FEATURE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FRIEDREICH ATAXIA; GENE; GENE MUTATION; HEART VENTRICLE HYPERTROPHY; HUMAN; INTRON; MITOCHONDRION; MOLECULAR PATHOLOGY; PREVALENCE; REVIEW; RNA TRANSCRIPTION;

ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; FRIEDREICH ATAXIA; HEART FAILURE; HUMANS; MUTATION; STROKE;

EID: 84865232176     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.57     Document Type: Review

References (97)

1. Campuzano V, Montermini L, Moltò MD et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271(5254), 1423-1427 (1996).
2. Dürr A, Cossee M, Agid Y et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N. Engl. J. Med. 335(16), 1169-1175 (1996).
3. Pandolfo M. Friedreich ataxia. Arch. Neurol. 65(10), 1296-1303 (2008).
4. Lynch DR, Farmer JM, Balcer LJ, Wilson RB. Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch. Neurol. 59(5), 743-747 (2002).
5. Pandolfo M. Molecular pathogenesis of Friedreich ataxia. Arch. Neurol. 56(10), 1201-1208 (1999).
6. Schöls L, Amoiridis G, Przuntek H, Frank G, Epplen JT, Epplen C. Friedreich's ataxia. Revision of the phenotype according to molecular genetics. Brain 120, 2131-2140 (1997).
7. Grabczyk E, Usdin K. The GAA*TTC triplet repeat expanded in Friedreich's ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner. Nucleic Acids Res. 28(14), 2815-2822 (2000).
8. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol. 2(10), 551-558 (2006).
9. Willis JH, Isaya G, Gakh O, Capaldi RA, Marusich MF. Lateral-flow immunoassay for the frataxin protein in Friedreich's ataxia patients and carriers. Mol. Genet. Metab. 94(4), 491-497 (2008).
10. Deutsch EC, Santani AB, Perlman SL et al. A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxia. Mol. Genet. Metab. 101(2-3), 238-245 (2010).
11. Saccà F, Puorro G, Antenora A et al. A combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design. PLoS ONE 6(3), e17627 (2011).
12. Nachbauer W, Wanschitz J, Steinkellner H et al. Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia. Mov. Disord. 26(10), 1935-1938 (2011).
13. Campuzano V, Montermini L, Lutz Y et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet. 6(11), 1771-1780 (1997).
14. Bidichandani SI, Ashizawa T, Patel PI. Atypical Friedreich ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triplet-repeat expansion. Am. J. Hum. Genet. 60(5), 1251-1256 (1997).
15. Cossée M, Dürr A, Schmitt M et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann. Neurol. 45(2), 200-206 (1999).
16. Forrest SM, Knight M, Delatycki MB et al. The correlation of clinical phenotype in Friedreich ataxia with the site of point mutations in the FRDA gene. Neurogenetics 1(4), 253-257 (1998).
17. Koutnikova H, Campuzano V, Foury F, Dollé P, Cazzalini O, Koenig M. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat. Genet. 16(4), 345-351 (1997).
18. Babcock M, de Silva D, Oaks R et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 276(5319), 1709-1712 (1997).
19. Pandolfo M, Pastore A. The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J. Neurol. 256(Suppl. 1), 9-17 (2009).
20. Bridwell-Rabb J, Winn AM, Barondeau DP. Structure-function analysis of Friedreich's ataxia mutants reveals determinants of frataxin binding and activation of the Fe-S assembly complex. Biochemistry 50(33), 7265-7274 (2011).
21. Lodi R, Rajagopalan B, Blamire AM et al. Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study. Cardiovasc. Res. 52(1), 111-119 (2001).
22. Lodi R, Hart PE, Rajagopalan B et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann. Neurol. 49(5), 590-596 (2001).
23. Bunse M, Bit-Avragim N, Riefflin A et al. Cardiac energetics correlates to myocardial hypertrophy in Friedreich's ataxia. Ann. Neurol. 53(1), 121-123 (2003).
24. Rötig A, de Lonlay P, Chretien D et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet. 17(2), 215-217 (1997).
25. Lobmayr L, Brooks DG, Wilson RB. Increased IRP1 activity in Friedreich ataxia. Gene 354, 157-161 (2005).
26. Richardson DR, Huang ML, Whitnall M, Becker EM, Ponka P, Suryo Rahmanto Y. The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia. J. Mol. Med. 88(4), 323-329 (2010).
27. Bayot A, Santos R, Camadro JM, Rustin P. Friedreich's ataxia: the vicious circle hypothesis revisited. BMC Med. 9, 112 (2011).
28. Tsou AY, Paulsen EK, Lagedrost SJ et al. Mortality in Friedreich ataxia. J. Neurol. Sci. 307(1-2), 46-49 (2011).
29. Giunta A, Maione S, Biagini R, Filla A, De Michele G, Campanella G. Noninvasive assessment of systolic and diastolic function in 50 patients with Friedreich's ataxia. Cardiology 75(5), 321-327 (1988).
30. Albano LM, Nishioka SA, Moysés RL et al. Friedreich's ataxia: cardiac evaluation of 25 patients with clinical diagnosis and literature review. Arq. Bras. Cardiol. 78(5), 444-451 (2002).
31. Child JS, Perloff JK, Bach PM, Wolfe AD, Perlman S, Kark RA. Cardiac involvement in Friedreich's ataxia: a clinical study of 75 patients. J. Am. Coll. Cardiol. 7(6), 1370-1378 (1986).
32. Harding AE, Hewer RL. The heart disease of Friedreich's ataxia: a clinical and electrocardiographic study of 115 patients, with an analysis of serial electrocardiographic changes in 30 cases. Q. J. Med. 52(208), 489-502 (1983).
33. Kipps A, Alexander M, Colan SD et al. The longitudinal course of cardiomyopathy in Friedreich's ataxia during childhood. Pediatr. Cardiol. 30(3), 306-310 (2009).
34. Malo S, Latour Y, Cote M, Geoffroy G, Lemieux B, Barbeau A. Electrocardiographic and vectocardiographic findings in Friedreich's ataxia. Can. J. Neurol. Sci. 3(4), 323-328 (1976).
35. Hewer R. The heart in Friedreich's ataxia. Br. Heart J. 31(1), 5-14 (1969).
36. Rodríguez JE, McCudden CR, Willis MS. Familial hypertrophic cardiomyopathy: basic concepts and future molecular diagnostics. Clin. Biochem. 42(9), 755-765 (2009).
37. Bit-Avragim N, Perrot A, Schöls L et al. The GAA repeat expansion in intron 1 of the frataxin gene is related to the severity of cardiac manifestation in patients with Friedreich's ataxia. J. Mol. Med. 78(11), 626-632 (2001).
38. Regner SR, Lagedrost SJ, Plappert T et al. Analysis of echocardiograms in a large heterogeneous cohort of patients with friedreich ataxia. Am. J. Cardiol. 109(3), 401-405 (2012).
39. Mottram PM, Delatycki MB, Donelan L, Gelman JS, Corben L, Peverill RE. Early changes in LV long-axis function in Friedreich ataxia: relation with the FXN gene mutation and cardiac structural change. J. Am. Soc. Echocardiogr. 24(7), 782-789 (2011).
40. Bhidayasiri R, Perlman SL, Pulst SM, Geschwind DH. Late-onset Friedreich ataxia: phenotypic analysis, magnetic resonance imaging findings, and review of the literature. Arch. Neurol. 62(12), 1865-1869 (2005).
41. Kelly M, Bagnall RD, Peverill RE et al. A polymorphic miR-155 binding site in AGTR1 is associated with cardiac hypertrophy in Friedreich ataxia. J. Mol. Cell. Cardiol. 51(5), 848-854 (2011).
42. Puccio H, Simon D, Cossée M et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 27(2), 181-186 (2001).
43. Al-Mahdawi S, Pinto RM, Varshney D et al. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics 88(5), 580-590 (2006).
44. Zhang J, Frerman FE, Kim JJ. Structure of electron transfer flavoprotein-ubiquinone oxidoreductase and electron transfer to the mitochondrial ubiquinone pool. Proc. Natl Acad. Sci. USA 103(44), 16212-16217 (2006).
45. Sutak R, Xu X, Whitnall M, Kashem MA, Vyoral D, Richardson DR. Proteomic analysis of hearts from frataxin knockout mice: marked rearrangement of energy metabolism, a response to cellular stress and altered expression of proteins involved in cell structure, motility and metabolism. Proteomics 8(8), 1731-1741 (2008).
46. Gregory SA, MacRae CA, Aziz K et al. Myocardial blood flow and oxygen consumption in patients with Friedreich's ataxia prior to the onset of cardiomyopathy. Coron. Artery Dis. 18(1), 15-22 (2007).
47. Schöls L, Zange J, Abele M et al. L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial. J. Neural Transm. 112(6), 789-796 (2005).
48. Raman SV, Phatak K, Hoyle JC et al. Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome. Eur. Heart J. 32(5), 561-567 (2011).
49. James TN, Cobbs BW, Coghlan HC, McCoy WC, Fisch C. Coronary disease, cardioneuropathy, and conduction system abnormalities in the cardiomyopathy of Friedreich's ataxia. Br. Heart J. 57(5), 446-457 (1987).
50. Quercia N, Somers GR, Halliday W, Kantor PF, Banwell B, Yoon G. Friedreich ataxia presenting as sudden cardiac death in childhood: clinical, genetic and pathological correlation, with implications for genetic testing and counselling. Neuromuscul. Disord. 20(5), 340-342 (2010).
51. Michael S, Petrocine SV, Qian J et al. Iron and iron-responsive proteins in the cardiomyopathy of Friedreich's ataxia. Cerebellum 5(4), 257-267 (2006).
52. Panas M, Gialafos E, Spengos K et al. Prevalence of interatrial block in patients with Friedreich's ataxia. Int. J. Cardiol. 145(2), 386-387 (2010).
53. Schadt KA, Friedman LS, Regner S, Mark GA, Lynch DR, Lin KS. Cross-sectional analysis of electrocardiograms in a large heterogeneous cohort of Friedreich ataxia subjects. J. Child Neurol. doi:10.1177/0883073812448461 (2012) (Epub ahead of print).
54. Ribaï P, Pousset F, Tanguy ML et al. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Arch. Neurol. 64(4), 558-564 (2007).
55. Asaad N, El-Menyar A, Al Suwaidi J. Recurrent ventricular tachycardia in patient with Friedreich's ataxia in the absence of clinical myocardial disease. Pacing Clin. Electrophysiol. 33(1), 109-112 (2010).
56. Lynch DR, Perlman SL, Meier T. A Phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch. Neurol. 67(8), 941-947 (2010).
57. Lagedrost SJ, Sutton MS, Cohen MS et al. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month Phase III study (IONIA). Am. Heart J. 161(3), 639.e1-645.e1 (2011).
58. Buyse G, Mertens L, Di Salvo G et al. Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring. Neurology 60(10), 1679-1681 (2003).
59. Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebocontrolled trial. Neurology 60(10), 1676-1679 (2003).
60. Dutka DP, Donnelly JE, Palka P, Lange A, Nunez DJ, Nihoyannopoulos P. Echocardiographic characterization of cardiomyopathy in Friedreich's ataxia with tissue Doppler echocardiographically derived myocardial velocity gradients. Circulation 102(11), 1276-1282 (2000).
61. Sutton MG, Olukotun AY, Tajik AJ, Lovett JL, Giuliani ER. LV function in Friedreich's ataxia. An echocardiographic study. Br. Heart J. 44(3), 309-316 (1980).
62. Dedobbeleer C, Rai M, Donal E, Pandolfo M, Unger P. Normal LV ejection fraction and mass but subclinical myocardial dysfunction in patients with Friedreich's ataxia. Eur. Heart J. Cardiovasc. Imaging 13(4), 346-352 (2012).
63. Weidemann F, Eyskens B, Mertens L et al. Quantification of regional right and LV function by ultrasonic strain rate and strain indexes in Friedreich's ataxia. Am. J. Cardiol. 91(5), 622-626 (2003).
64. Gersh BJ, Maron BJ, Bonow RO et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Thorac. Cardiovasc. Surg. 142(6), e153-e203 (2011).
65. Bruder O, Wagner A, Jensen CJ et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 56(11), 875-887 (2010).
66. Meyer C, Schmid G, Görlitz S et al. Cardiomyopathy in Friedreich's ataxiaassessment by cardiac MRI. Mov. Disord. 22(11), 1615-1622 (2007).
67. Rajagopalan B, Francis JM, Cooke F et al. Analysis of the factors influencing the cardiac phenotype in Friedreich's ataxia. Mov. Disord. 25(7), 846-852 (2010).
68. Kosutic J, Zamurovic D. High-dose beta-blocker hypertrophic cardiomyopathy therapy in a patient with Friedreich ataxia. Pediatr. Cardiol. 26(5), 727-730 (2005).
69. Murphy CJ, Oudit GY. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J. Card. Fail. 16(11), 888-900 (2010).
70. Hart PE, Lodi R, Rajagopalan B et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch. Neurol. 62(4), 621-626 (2005).
71. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 6(10), 878-886 (2007).
72. Lynch DR, Willi SM, Wilson RB et al. EPI-A0001: new potential therapy for Friedreich ataxia. Presented at: 136th Annual Meeting of the American Neurological Association. San Diego, CA, USA, 25-27 September 2011.
73. Boddaert N, Le Quan Sang KH, Rötig A et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110(1), 401-408 (2007).
74. Velasco-Sánchez D, Aracil A, Montero R et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 10(1), 1-8 (2011).
75. Tsou AY, Friedman LS, Wilson RB, Lynch DR. Pharmacotherapy for Friedreich ataxia. CNS Drugs 23(3), 213-223 (2009).
76. Longo F, Genisio M, Piga A. Effects of Deferiprone on cardiac disease in patients with Friedreich ataxia. Presented at: Fourth International Conference on Friedreich Ataxia. Strasbourg, France, 5 May 2011.
77. Arpa J, Delatycki M, Munnich A et al. A six-month double-blind, randomized, placebo-controlled study investigating the safety and tolerability of deferiprone in subjects with Friedreich's ataxia. Presented at: Fourth International Conference on Friedreich Ataxia. Strasbourg, France, May 5 2011.
78. Marmolino D, Manto M, Acquaviva F et al. PGC-1alpha down-regulation affects the antioxidant response in Friedreich's ataxia. PLoS ONE 5(4), e10025 (2010).
79. Coppola G, Marmolino D, Lu D et al. Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia. Hum. Mol. Genet. 18(13), 2452-2461 (2009).
80. García-Giménez JL, Sanchis-Gomar F, Pallardó FV. Could thiazolidinediones increase the risk of heart failure in Friedreich's ataxia patients? Mov. Disord. 26(5), 769-771 (2011).
81. García-Giménez JL, Gimeno A, Gonzalez-Cabo P et al. Differential expression of PGC-1a and metabolic sensors suggest age-dependent induction of mitochondrial biogenesis in Friedreich ataxia fibroblasts. PLoS ONE 6(6), e20666 (2011).
82. Boesch S, Sturm B, Hering S et al. Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: a clinical pilot trial. Mov. Disord. 23(13), 1940-1944 (2008).
83. Boesch S, Sturm B, Hering S, Goldenberg H, Poewe W, Scheiber-Mojdehkar B. Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin. Ann. Neurol. 62(5), 521-524 (2007).
84. Acquaviva F, Castaldo I, Filla A et al. Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression. Cerebellum 7(3), 360-365 (2008).
85. Tilling L, Clapp B. Erythropoietin: a future therapy for failing hearts? Heart Fail. Rev. 17(3), 475-483 (2012).
86. Rai M, Soragni E, Jenssen K et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 3(4), e1958 (2008).
87. Rai M, Soragni E, Chou CJ et al. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS ONE 5(1), e8825 (2010).
88. Sandi C, Pinto RM, Al-Mahdawi S et al. Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol. Dis. 42(3), 496-505 (2011).
89. Sun Z, Singh N, Mullican SE et al. Diet-induced lethality due to deletion of the Hdac3 gene in heart and skeletal muscle. J. Biol. Chem. 286(38), 33301-33309 (2011).
90. Coskun KO, Popov AF, Schmitto JD et al. Feasibility of implantable cardioverter defibrillator treatment in five patients with familial Friedreich's ataxia-a case series. Artif. Organs 34(11), 1061-1065 (2010).
91. Yoda M, El-Banayosy A, Arusoglu L, Tendrich G, Minami K, Körfer R. Permanent use of a ventricle assist device for dilated cardiomyopathy in Friedreich's ataxia. J. Heart Lung Transplant. 25(2), 251-252 (2006).
92. Leonard H, Forsyth R. Friedreich's ataxia presenting after cardiac transplantation. Arch. Dis. Child. 84(2), 167-168 (2001).
93. Sedlak TL, Chandavimol M, Straatman L. Cardiac transplantation: a temporary solution for Friedreich's ataxia-induced dilated cardiomyopathy. J. Heart Lung Transplant. 23(11), 1304-1306 (2004).
94. Vyas PM, Tomamichel WJ, Pride PM et al. A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model. Hum. Mol. Genet. 21(6), 1230-1247 (2012).
95. Günal N, Saraçlar M, Ozkutlu S, Senocak F, Topalölu H, Karaaslan S. Heart disease in Friedreich's ataxia: a clinical and echocardiographic study. Acta Paediatr. Jpn. 38(4), 308-311 (1996).
96. De Michele G, Di Maio L, Filla A et al. Childhood onset of Friedreich ataxia: a clinical and genetic study of 36 cases. Neuropediatrics 27(1), 3-7 (1996).
97. Alboliras ET, Shub C, Gomez MR et al. Spectrum of cardiac involvement in Friedreich's ataxia: clinical, electrocardiographic and echocardiographic observations. Am. J. Cardiol. 58(6), 518-524 (1986).